The effect of Cornus mas L. fruit extract supplementation on glycemic control, insulin resistance, and adiponectin levels in patients with metabolic dysfunction-associated steatotic liver disease: a double-blind randomized controlled clinical trial.

Adiponectin levels significantly decreased after 12 weeks versus baseline in the placebo group among the total population.

• ITT approach baseline median: 610.0 (430.0 to 710.0), after 12 weeks: 460.0 (390.0 to 580.0); P = 0.01
• No significant difference was found when comparing the placebo group to the CMFE group for this change
• Study duration was 12 weeks with 50 MASLD patients enrolled, 40 completing the study

Adiponectin levels significantly decreased after 12 weeks versus baseline in the placebo group among women specifically.

• ITT approach baseline median: 675.0 (605.0 to 742.50), after 12 weeks: 435.0 (417.5 to 582.50); P = 0.01
• No significant difference was found when comparing the placebo group to the CMFE group overall in women
• This decline was not observed at a statistically significant level in the CMFE group

A significant difference in the trend of adiponectin level changes between placebo and CMFE groups was found in women at the end of the study.

• ITT approach: Placebo group change: -220.0 (-290 to -37.50), CMFE group change: -10.0 (-210.0 to 172.5); P = 0.01
• This between-group difference in adiponectin change was only statistically significant in women, not in the total population
• This suggests a protective effect of CMFE on adiponectin levels in women with MASLD

CMFE supplementation had no significant effect on glycemic control or insulin resistance indices.

• P > 0.05 for all glycemic and insulin resistance outcomes
• Outcomes assessed included fasting plasma glucose, fasting insulin, HOMA-IR, triglyceride and glucose index, metabolic score for insulin resistance, QUICKI, and visceral adiposity index
• Measurements were taken at baseline and after 12 weeks of intervention

The trial was a double-blind randomized controlled clinical trial in MASLD patients receiving CMFE at 20 cc/day providing 32 mg/day total anthocyanin for 12 weeks.

• 50 MASLD patients were enrolled and randomized into CMFE or placebo groups
• 40 individuals completed the study: CMFE group n = 18, placebo group n = 22
• The dose of 20 cc/day CMFE provided 32 mg/day total anthocyanin
• Both intention-to-treat (ITT) analyses were conducted
• Registered at Iranian Registry of Clinical Trials under code IRCT20180419039359N1